neutropenia or neutropenia from other causes among patients taking clopidogrel in CAPRIE from the neutropenia seen in Ͼ1% of patients treated with ticlopidine for greater than 1 month in whom profound life-threatening neutropenia develops requiring cessation of the drug and often requiring therapeutic interventions. This sort of severe neutropenia did not occur in any of the more than 9,000 patients in CAPRIE treated with clopidogrel and has been reported very rarely in the greater than 4 million people treated with clopidogrel since the drug was approved for use in the United States based on post-market surveillance (Dr. Melvin Blumenthal, MD, Bristol-Myers Squibb, personal communication).
Improvement of Myocardial Blood Flow to Ischemic Regions by Angiotensin-Converting Enzyme Inhibition
Schneider et al. (1) analyzed the effects of acute angiotensinconverting enzyme (ACE) inhibition on myocardial blood flow (MBF) in ischemic and nonischemic regions of 10 symptomatic patients with coronary artery disease (CAD). They used [ 15 O] water positron emission tomography at rest and during maximal dobutamine stress before and after angiotensin converting enzyme (ACE) inhibition and demonstrated that quinaprilat 10 mg intravenous was able to improve MBF to ischemic regions in patients with CAD.
There is some experimental and clinical evidence that ACE inhibitors can increase regional oxygen supply to ischemic areas of myocardium through a redistribution of regional blood flow in humans and animals (2-7). However, there is not evidence that ACE-inhibitors are able to improve the main clinical outcomes in evaluation of anti-ischemic efficacy of cardiovascular drugs as angina, ST segment depression and echocardiographic wall motion abnormalities during exercise or pharmacological stress test. In this regard we demonstrated, using exercise and dipyridamole echocardiographic stress tests, that neither captopril nor enalapril (sulfhydryl and not sulfhydryl ACE-inhibitors, respectively) had a significant antiischemic effect in patients with stable angina pectoris (8) .
In our point of view, the main questions are: 
REPLY
We appreciate the interest of Dr. Langobardi and his colleagues concerning our analysis of the antiischemic effect of 10 mg quinapril (intravenous) assessed by 15 O water positron emission tomography (PET) (1) and questioning the clinical value of our observation. The clear advantage of the PET technique we have used is the noninvasive, quantitative analysis of changes in regional myocardial blood flow, which is currently only possible with positron tracers. Using this technique a significant improvement in myocardial blood flow after quinaprilat intravenous could be demonstrated. We agree with Dr. Langobardi that the incidence of clinical signs of ischemia was low in our patient population as it was observed by others in patients with coronary artery disease undergoing dobutamine-stress (2). However, the PET technique enabled us to detect very early changes in myocardial blood flow before these clinical signs of ischemia eventually developed. Since we know that the presence of clinical signs of ischemia are inconsistent, subjective and variable in the same patient, we decided to focus on quantifiable, regional measures of myocardial blood flow.
In contrast to Dr. Langobardi's statement, there are data about the anti-ischemic effect of quinapril on clinical variables of myocardial ischemia in patients with coronary artery disease. Bussmann et al. (3) have previously reported the results of a randomized, double-blind, cross-over study of 16 men with coronary artery disease receiving oral quinapril or placebo. They were able to show that quinapril (10 mg) lead acutely, and after two weeks of treatment, to a significant reduction in the extent of ST depression during exercise electrocardiogram.
Taken together these data indicate that quinapril has an antiischemic potential. However, we agree with Dr. Langobardi and have this clearly stated in our paper, that we do not treat myocardial blood flow values but patients with coronary artery disease. Therefore, the unique, anti-ischemic potential of quinapril in the treatment of patients with coronary artery disease must be substantiated in large clinical trials. From our data quinapril seems to be a promising choice for such studies. 
